540 research outputs found

    Study of Hybrid Detector Sensitivity by Coincidence Scanning Technique

    Get PDF

    On the β-detection efficiency of a combined Si and plastic stack detector for DESPEC

    Get PDF
    A Geant4 simulation has been carried out in order to determine the B-detection efficiency of a rare isotope beam implantation setup, for decay spectroscopy experiments, comprising a number of Double Sided Silicon Strip Detectors (DSSSDs) and two plastic scintillation detectors placed upstream and downstream. The absolute efficiency for the emitted B-particle detection from radioactive fragments implanted in the DSSSDs using fast-timing plastic-scintillator detector, is calculated. The detection efficiency of the setup has been studied with two different distances between the Si layers and plastics. The requirement for the thickness of the Si detector layers and its implication on the B-detection effciency has been investigated for 1 mm and 300 um thickness of Si layers. The combined efficiency of DSSSD and plastic detectors were also simulated for two different thicknesses of the DSSSD

    Veronese and Segre morphisms between non-commutative projective spaces

    Get PDF
    Number theory, Algebra and Geometr

    Isomeric ratios in Hg-206

    Get PDF
    T. Alexander et al.; 5 págs.; 2 figs.; 1 tab.; PACS numbers: 25.70.Mn, 23.35.+g, 27.80.+w; Presented at the Zakopane Conference on Nuclear Physics “Extremes of the Nuclear Landscape”, Zakopane, Poland, August 31–September 7, 2014.206Hg was populated in the fragmentation of an E∕A = 1 GeV 208Pb beam at GSI. It was part of a campaign to study nuclei around 208Pb via relativistic Coulomb excitation. The observation of the known isomeric states confirmed the identification of the fragmentation products. The isomeric decays were also used to prove that the correlations between beam identification detectors and the AGATA γ-ray tracking array worked properly and that the tracking efficiency was independent of the time relative to the prompt flash.Peer Reviewe

    Survival of patients treated with extended-hours haemodialysis in Europe : an analysis of the ERA-EDTA Registry

    Get PDF
    Background. Previous US studies have indicated that haemodialysis with >= 6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients. Methods. We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association-European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5-4h/treatment), EHD (three times weekly, >= 6h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders. Results. From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.10.8h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 +/- 0.2h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62-0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71-0.90)]. Conclusions. EHD is associated with better survival in European patients treated with haemodialysis three times weekly.Peer reviewe

    A population-based survey of Chronic REnal Disease In Turkey—the CREDIT study

    Get PDF
    Background. Chronic kidney disease (CKD) is a growing health problem worldwide that leads to end-stage kidney failure and cardiovascular complications. We aimed to determine the prevalence of CKD in Turkey, and to evaluate relationships between CKD and cardiovascular risk factors in a population-based survey

    Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report

    Get PDF
    Mullerian adenosarcoma with sarcomatous overgrowth (MASO) is a rare variant of uterine sarcomas, associated with postoperative recurrence, metastases and a fatal outcome. The mean age at diagnosis is 54.5 years. A 37-year-old nullipara presented with irregular vaginal bleeding, a normal pelvic examination, and an initially negative ultrasound. Repeat ultrasound one month later revealed an 11-cm heterogeneous pelvic mass. She underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Pathology confirmed uterine MASO. Computed tomography 2 weeks postoperatively showed a huge mass compatible with recurrence. Patient died 2 weeks later. MASO is rarely diagnosed in women in their 4th decade. This case stresses that these aggressive tumors should be considered in the differential of patients with vaginal bleeding and pelvic masses irrespective of their age

    Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment

    Get PDF
    Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients

    Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease:a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

    Get PDF
    Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.</p
    corecore